FDA Grants RMAT Designation to Tenaya's TN-401 Gene Therapy for PKP2-Associated ARVC
核心洞察
The FDA granted Regenerative Medicine Advanced Therapy designation to TN-401, Tenaya Therapeutics' AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (搜索).
The designation was supported by interim RIDGE-1 Phase 1b/2 data showing reduced daily rates of premature ventricular contractions and non-sustained ventricular tachycardias after a single infusion.
TN-401 already holds FDA Orphan Drug and Fast Track designations plus European Medicines Agency (搜索) PRIME designation, and Tenaya plans a pivotal trial.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced on Sept. 14, 2026, that the U.S. Food and Drug Administration (搜索) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401, the company's investigational AAV9-based gene therapy for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy (搜索) (ARVC).
The designation was supported by interim data from the ongoing RIDGE-1 Phase 1b/2 clinical trial, which showed improvements in multiple electrical stability measures, including reduced rates of premature ventricular contractions (PVCs) and non-sustained ventricular tachycardias (NSVTs) — two of the most frequently occurring forms of ventricular arrhythmias that characterize ARVC. Tenaya's RMAT application included data presented at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting in May 2026.
"RMAT designation underscores the continued recognition by regulators of the seriousness of PKP2 (搜索)-associated ARVC and the potential of TN-401 gene therapy to change the course of disease by addressing its underlying cause," said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics. "This designation is supported by the encouraging interim data generated to date from our RIDGE-1 trial, which demonstrated clinically meaningful reductions in daily rates of PVCs and NSVTs, as well as a favorable tolerability profile."
Ali added that RMAT, together with Fast Track and Orphan Drug designations, enhances the company's ability to engage with the FDA as it works to advance TN-401 toward a pivotal trial.
What RMAT Designation Provides
RMAT is an FDA expedited program intended to facilitate the development and review of regenerative medicine therapies for serious conditions where preliminary clinical evidence indicates the potential to address unmet medical needs. The designation provides enhanced opportunities for interaction with the FDA, including early and ongoing guidance regarding clinical development, manufacturing and potential regulatory pathways, and it may provide eligibility for accelerated approval, priority review and rolling review.
TN-401 previously received Orphan Drug and Fast Track designations from the FDA, as well as PRIME designation from the European Medicines Agency (搜索). Development of TN-401 is supported in part by a grant from the California Institute for Regenerative Medicine (搜索) (CIRM).
Disease Burden and Unmet Need
Plakophilin-2 (PKP2 (搜索)) mutations are the most common genetic cause of ARVC, also known as arrhythmogenic cardiomyopathy (ACM), occurring in approximately 40 percent of the overall ARVC population. The prevalence of PKP2-associated ARVC is estimated at more than 70,000 people in the U.S. alone.
In PKP2 (搜索)-associated ARVC, mutations of the PKP2 gene result in insufficient expression of a protein needed for the proper functioning of the desmosomal complex that maintains physical connections and electrical signaling between heart muscle cells. As the desmosome structure degrades, cardiac muscle cells are replaced by fibrofatty tissue and electrical pulses in the heart become unstable, resulting in potentially life-threatening heart rhythms. Symptoms include arrhythmias, palpitations, lightheadedness, dizziness and fainting. The condition is typically diagnosed before age 40, and sudden cardiac arrest due to ventricular arrhythmia is frequently the first manifestation of disease.
Current treatments include anti-arrhythmic medications, implantable cardioverter-defibrillators (ICDs) and ablation procedures, none of which address the underlying genetic cause of disease.
RIDGE-1 Trial Design
TN-401 is designed to deliver the PKP2 (搜索) gene using an AAV9 vector. According to Tenaya, AAV9 was selected based on its extensive clinical and commercial safety record and demonstrated ability to target heart muscle cells.
The RIDGE-1 Phase 1b/2 trial (NCT06228924) is a multi-center, open-label, dose-escalation study being conducted in the U.S. and UK. It is intended to assess the safety, tolerability and preliminary clinical efficacy of a one-time intravenous infusion of TN-401. The trial seeks to enroll up to fifteen adults diagnosed with PKP2 (搜索)-associated ARVC who have an ICD and are at increased risk for arrhythmias as determined by premature ventricular count (PVC) during screening.
As part of its TN-401 development program, Tenaya is also conducting the RIDGE natural history study (NCT06311708), which the company believes is the largest natural history study of adults with PKP2 (搜索)-associated ARVC.
Next Steps
Tenaya said it expects to share additional data from RIDGE-1 in the fourth quarter of 2026 and to provide an update on its ongoing discussions with regulators regarding pivotal trial plans for TN-401. The company's pipeline also includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (搜索) (HCM), and TN-301, a small molecule HDAC6 inhibitor being explored in cardiac, metabolic and muscular conditions including heart failure with preserved ejection fraction (搜索) (HFpEF) and Duchenne muscular dystrophy (搜索) (DMD).